Foamix Pharmaceuticals Doses First Patient in Phase 3 Trial

Foamix Pharmaceuticals Doses First Patient in Phase 3 Trial

Foamix Pharmaceuticals has dosed the first patient in its phase 3 program to evaluate the efficacy and safety of its topical minocycine foam 1.5%, FMX103, for the treatment of moderate-to-severe rosacea. The design and clinical endpoints for this phase 3 program are based on the results of the company’s phase 2 study, conducted in Germany with 233 rosacea patients, and recent end-of-phase 2 meeting with the FDA. The company expects […]

Read More ˃